Graft Polymer CEO discusses proposed Awakn acquisition; rebrand to Solvonis

Proactive - Interviews for investors

Graft Polymer (UK) PLC (LSE:GPL) CEO Anthony Tennyson talked with Proactive's Stephen Gunnion about the company’s plans to acquire Canadian biotech Awakn Life Sciences. Tennyson explained the rationale behind this strategic move, highlighting Awakn's robust clinical-stage pipeline that offers significant opportunities in addressing alcohol use disorder (AUD). The acquisition includes two core programs: AWKN001, targeting severe AUD in the UK, and AWKN002, targeting moderate to severe AUD in the US. Tennyson emphasised the de-risked nature of these assets, particularly the phase three AWKN001 trial, which is two-thirds funded by the UK Department of Health. Notably, results from earlier trials demonstrated abstinence rates improving from 2% to 86% post-treatment. Additionally, Tennyson discussed the planned rebrand of Graft Polymer to Solvonis Therapeutics PLC. The rebranding aligns with the company’s vision of becoming a leading neuropsychiatry firm focused on addiction and mental health treatments. He noted the acquisition brings valuable talent and clinical-stage programs to Graft Polymer, positioning it for near-to-medium-term revenue generation. This move, Tennyson believes, significantly benefits Graft shareholders by providing a de-risked pipeline and growth opportunities. For more updates on Graft Polymer’s journey, visit Proactive’s YouTube channel. Don’t forget to like, subscribe, and enable notifications for future content. #GraftPolymer #SolvonisTherapeutics #AwaknLifeSciences #AddictionTreatment #AlcoholUseDisorder #Neuropsychiatry #Phase3Trials #HealthcareInnovation #BiotechNews #ProactiveInvestors#ProactiveInvestors#invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews